Xenetic Biosciences, Inc. (XBIO)
| Market Cap | 14.26M |
| Revenue (ttm) | 571,409 |
| Net Income (ttm) | -11.06M |
| Shares Out | 8.75M |
| EPS (ttm) | -1.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $1.67 |
| Previous Close | $1.57 |
| Change ($) | 0.10 |
| Change (%) | 6.37% |
| Day's Open | 1.61 |
| Day's Range | 1.57 - 1.69 |
| Day's Volume | 49,122 |
| 52-Week Range | 0.76 - 5.85 |
Continued Execution on Xcart™ Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind-Enabling Studies in the United States Licensing Partn...
Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a...
- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States - Study wil...
Driving development of XCART™ platform and leveraging academic collaborations through preclinical development Recent clinical, regulatory and commercial advancements from licensing partners leveraging P...
FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform...
FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platf...
FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platfo...
Shares of Xenetic Biosciences Inc (NASDAQ: XBIO), a drug delivery platform company, were ripping higher Wednesday on markedly above-average volume. What Happened: The Framingham, Massachusetts-based com...
Shares of Xenetic Biosciences Inc. skyrocketed on massive volume toward a 17-month high in morning trading Wednesday, after the Massachusetts-based biopharmaceutical company said its partner PJSC Pharms...
The stock price of Xenetic Biosciences, Inc. (NASDAQ:XBIO) are trading at over 300% as it went from $1.08 in the previous close to $4.88 as of 11:17 AM ET. This is why it happened.
Xenetic Biosciences (XBIO) news for Wednesday includes positive news from a Phase 3 clinical trial boosting XBIO stock higher. The post Xenetic Biosciences News: Why XBIO Stock Is Going Ballistic Today ...
Nano-cap biotech Xenetic Biosciences Inc.'s stock was rallying Friday following an announcement concerning pricing for its previously announced offering of common stock and accompanying warrants.
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, ... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol XBIO |
Financial Performance
In 2020, XBIO's revenue was $436,942, an increase of 2,460.31% compared to the previous year's $17,066. Losses were -$10.89 million, -14.73% less than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for XBIO stock is "Buy." The 12-month stock price forecast is 5.00, which is an increase of 199.40% from the latest price.